Short answer
Semax research peptide is a synthetic heptapeptide analog of the adrenocorticotropic hormone fragment ACTH(4-10), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is studied in cognitive research models for effects on dopaminergic and serotonergic signaling, BDNF regulation, and cholinergic neuron activity. It is sold as a lyophilized research powder and is not for human use.
What is the Semax research peptide?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analog of the fragment ACTH(4-10) of adrenocorticotropic hormone, retaining the melanocortin core residues while a C-terminal Pro-Gly-Pro extension is designed to increase metabolic stability relative to the native fragment.
As an ACTH(4-10) analog, Semax is studied for its reported effects on learning, memory, and attention in cognitive research models, without the classical hormonal actions of full-length adrenocorticotropic hormone. The peptide is generally supplied as a lyophilized powder and reconstituted in the laboratory according to standard peptide handling protocols.
ACTH(4-10) analog lineage and nootropic research peptide context
The ACTH(4-10) fragment was studied for decades for its behavioral effects, independent of the endocrine functions of the parent hormone. Researchers found that the N-terminal portion of ACTH, which does not stimulate the adrenal cortex, nevertheless produced measurable effects on learning and attention in animal models. Semax was developed to preserve these behavioral effects in a small, stabilized peptide.
Within the field, Semax is often classified as a nootropic research peptide because its published effects are concentrated on cognitive and neurotrophic parameters rather than on classic hormone signaling. PEPMAKE groups it in the nootropic research category alongside other peptides studied for learning, memory, and stress-related behavior.
Mechanism of action: dopaminergic and serotonergic systems
Eremin and colleagues examined the effects of Semax on monoaminergic brain systems in rodents. The study reported that Semax significantly increased tissue levels of the serotonin metabolite 5-HIAA in the striatum, and that extracellular 5-HIAA rose substantially within one to four hours after administration, indicating activation of the serotonergic system. Semax alone did not alter tissue or extracellular dopamine concentrations, but when administered before D-amphetamine it dramatically enhanced the amphetamine-induced increase in extracellular dopamine and amplified the associated increase in locomotor activity [1].
These findings position the dopaminergic and serotonergic systems as part of the reported mechanism of Semax, with the peptide acting as a modulator of monoaminergic transmission rather than as a direct receptor agonist. This nuance is important when comparing Semax to compounds that act through a single receptor target.
Research findings: BDNF and trkB regulation
A second major line of research concerns the neurotrophic system. Dolotov and colleagues reported that a single intranasal application of Semax in rats increased BDNF protein levels in the hippocampus, increased trkB tyrosine phosphorylation, and increased exon III BDNF and trkB messenger RNA expression. These molecular changes were accompanied by a distinct increase in conditioned avoidance reactions, indicating improved learning in the test paradigm [2].
A related study examined Semax in the basal forebrain. Dolotov and colleagues demonstrated that tritium-labeled Semax binds specifically, reversibly, and in a time-dependent manner to membranes from the basal forebrain, and that intranasal Semax produced a rapid increase in BDNF levels in the basal forebrain but not in the cerebellum [4]. The results suggest the existence of specific Semax binding sites in this region and associate the peptide's cognitive effects, at least in part, with increased BDNF protein levels.
Research findings: cholinergic neuron activity
Grivennikov and colleagues studied the ACTH(4-10) analog in primary cultures of rat basal forebrain neurons. Semax increased the survival of cholinergic basal forebrain neurons by approximately 1.5- to 1.7-fold and, at 100 nM, stimulated the activity of choline acetyltransferase, the enzyme responsible for acetylcholine synthesis. The peptide did not affect GABAergic neurons, total neuron-specific enolase-positive neurons, or glial cell proliferation, suggesting a degree of selectivity for cholinergic cells [3].
Because cholinergic neurons of the basal forebrain are a focus of research on age-related cognitive decline, these in vitro findings have made Semax a recurring subject in studies of cholinergic signaling. The authors of the report note that the implications for any clinical condition remain to be clarified [3].
Research history of Semax
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, where it emerged from research on the behavioral effects of ACTH fragments. The peptide has been studied since the 1990s, with early work establishing its nootropic-like behavioral profile and later work dissecting the underlying molecular mechanisms.
The published record spans animal behavioral studies, receptor binding assays, ex vivo neurotrophin measurements, and cell culture experiments. Journals represented in the literature include Neurochemical Research, Brain Research, Restorative Neurology and Neuroscience, and the Journal of Neurochemistry.
Interpreting the research record
Read together, the published studies on Semax point to three converging lines of evidence rather than a single mechanism. The monoaminergic line shows modulation of dopaminergic and serotonergic transmission, most clearly seen as an enhancement of amphetamine-stimulated dopamine release in the striatum [1]. The neurotrophic line shows regulation of BDNF protein and trkB signaling in the hippocampus and basal forebrain [2][4]. The cholinergic line shows increased survival of cholinergic basal forebrain neurons and stimulation of choline acetyltransferase in vitro [3].
A few interpretive cautions are worth stating explicitly for researchers new to this literature. First, the BDNF effects are region-specific: intranasal Semax increased BDNF in the basal forebrain but not in the cerebellum, which argues against a global neurotrophin surge and in favor of targeted, region-dependent regulation [4]. Second, the cholinergic findings come from cultured primary neurons, and in vitro conditions do not reproduce the full complexity of an intact brain [3]. Third, the monoamine findings were obtained in rodents, and the interactions observed with D-amphetamine describe a modulation of an existing pharmacological response rather than an independent effect [1].
For a research protocol, these distinctions matter. If the goal is to study BDNF signaling, the hippocampal and basal forebrain regulation documented by Dolotov and colleagues is the most directly relevant line [2][4]. If the goal is to study cholinergic biology, the primary-culture data on neuronal survival and choline acetyltransferase activity are the relevant evidence [3]. Treating the three lines as interchangeable would overstate the support for any single mechanism.
Research applications in cognitive and neurotrophic studies
Because Semax is a small, stabilized heptapeptide with a documented behavioral pharmacology, it is used in a range of experimental designs. In cognitive research, the peptide has been evaluated in learning and memory paradigms, where the improvement in conditioned avoidance reactions accompanied the BDNF changes in the hippocampus [2]. In neurotrophic studies, it provides a tool for investigating how an exogenous peptide modulates BDNF and trkB expression in vivo and in cell culture. In cholinergic research, the primary-neuron survival data offer a starting point for studies of factors that support basal forebrain cholinergic neurons [3].
For laboratories evaluating the compound, the practical considerations are straightforward: confirm HPLC purity, mass-spectrometry identity against the theoretical mass of Met-Glu-His-Phe-Pro-Gly-Pro, and a batch-specific COA before use. PEPMAKE provides batch documentation through the batch verification portal, and the Semax product page shows the documentation supplied with each order.
Semax compared with related nootropic research peptides
Semax is frequently discussed alongside Selank, another synthetic heptapeptide sharing the C-terminal Pro-Gly-Pro motif. The two compounds are sometimes confused because of their structural similarity, but their research profiles differ: Semax is an ACTH(4-10) analog studied in cognitive research models, whereas Selank is a tuftsin analog studied for anxiolytic-like and immunomodulatory activity. Our Selank research peptide article covers the tuftsin analog in detail. For laboratories that wish to study both compounds, PEPMAKE offers a Semax + Selank Blend.
How to evaluate quality when buying Semax for research
Research-grade Semax should come with verifiable quality data. Before ordering, confirm the following:
PEPMAKE provides batch documentation through the batch verification portal, and the Semax product page shows the documentation supplied with each order. PEPMAKE products are supplied for in-vitro laboratory research only.
Storage and handling of lyophilized Semax
Lyophilized Semax is most stable when stored cold and dry. Standard laboratory guidance includes storing the powder at or below -20 degrees C, protecting it from light and moisture, and minimizing repeated exposure to ambient temperature. After reconstitution with an appropriate laboratory-grade solvent, aliquoting the solution helps avoid repeated freeze-thaw cycles. Always follow the manufacturer's documentation and your laboratory's stability protocol, and keep the compound clearly labeled for research use only.
Summary
Semax is a synthetic ACTH(4-10) analog heptapeptide studied in cognitive research models for its reported effects on monoaminergic signaling, BDNF/trkB regulation, and cholinergic neuron survival. Its value as a research tool rests on a well-characterized literature spanning behavioral, neurochemical, and cell-based experiments, together with its small, stabilized structure that makes it straightforward to source and handle as a lyophilized research powder. As with all research peptides, verify HPLC purity, mass-spectrometry identity, and batch-specific COA before use.
FAQ
What is Semax?
Semax is a synthetic heptapeptide (sequence Met-Glu-His-Phe-Pro-Gly-Pro) that is an analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. It is sold for laboratory research only.
How does Semax differ from Selank?
Both are synthetic heptapeptides sharing a Pro-Gly-Pro motif, but Semax is an ACTH(4-10) analog studied in cognitive research models, while Selank is a tuftsin analog studied for anxiolytic-like and immunomodulatory activity.
Is Semax for human use?
No. PEPMAKE sells Semax as a lyophilized powder for in-vitro laboratory research only. It is not for human or animal consumption.
What purity should research-grade Semax have?
At least 99% purity measured by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA).